{"id":441599,"date":"2021-02-23T07:03:24","date_gmt":"2021-02-23T12:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441599"},"modified":"2021-02-23T07:03:24","modified_gmt":"2021-02-23T12:03:24","slug":"iteos-to-present-at-upcoming-investor-conferences-in-march","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/","title":{"rendered":"iTeos to Present at Upcoming Investor Conferences in March"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb.  23, 2021  (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming virtual investor conferences in March:<\/p>\n<p>\n        <u>Cowen 41<\/u><br \/>\n        <sup><br \/>\n          <u>st<\/u><br \/>\n        <\/sup><br \/>\n        <u> Annual Health Care Conference<\/u><br \/>\n        <br \/>Date: Tuesday, March 2, 2021<br \/>Time: 11:50 a.m. ET<\/p>\n<p>\n        <u>H.C. Wainwright Global Life Sciences Conference<\/u><br \/>\n        <br \/>Date: Tuesday, March 9, 2021<br \/>Time: 7:00 a.m. ET<\/p>\n<p>A live webcast of each presentation will be available on the Investors section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QoqQuEdXlzg75NICjie9BVCSlYMzP8RK0GEdwQr1TpZP00x2jAW3J0w7d3PR4QhvIrzhjcHHCjiVMPsm_hZ4BuCfF2QIay59A3Mu2yuhRDsGIqTF4OlBVl-LjJgRZ0um\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.iteostherapeutics.com<\/a>. An archived replay will be available for approximately 30 days following the presentation.<\/p>\n<p>\n        <strong>About iTeos Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate,\u00a0inupadenant, is designed as a highly selective small molecule antagonist of the adenosine A2A\u00a0receptor, in the adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors.\u00a0Inupadenant\u00a0is being investigated in an open-label multi-arm Phase 1\/2a clinical trial in adult cancer patients with advanced solid tumors and encouraging preliminary single-agent activity was observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also selected to engage the Fc gamma receptor and to promote antibody-dependent cellular cytotoxicity activity. An open-label Phase 1\/2a clinical trial of EOS-448 was initiated in adult cancer patients with advanced solid tumors. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.<\/p>\n<p>\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Ryan Baker <br \/>iTeos Therapeutics, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hIAYmWSo6j9n_u8JT9gXkyLCy7eEiv-53kwKfV4QyhOq2mWjhEdxyU01M1siCvMenAQI3Qog9EEO8mtkl43jf-3jROangPv9apCmNIOu_plimD-wBAedtD7a2NAZFB7B\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Ryan.Baker@iteostherapeutics.com<\/a><\/p>\n<p>\n        <strong>Media Contacts:<\/strong><br \/>\n        <br \/>Amber Fennell, Paul Kidwell<br \/>Consilium Strategic Communications<br \/>+44 203 709 5700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QkRsZ8h13tWPjvDbpXvBbC0TUHUMFZHQU2_H1ciby70zGC-iLLXvWdvoaNb6OCR6vNEknzg3zp6JPG1D8eautt1f-TJ_RJO_Rzf4ZU3kBbhiYTDxqAjw3U0fkYlNYYJbD0fdu2pYoIJNh2TLd-cGC4WF862HveSJwU4I8zUdRaneKELArBQ5xHfE1t2sMWPHfvHrBh2JvqG3lLC5AAdyP_WtipPigNhOIJL837f8AUhwnck62NddoZ2NJRamwa4xaR15l3qZi0Ee3IhvsT9B4A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">iteos@consilium-comms.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/1af60df3-d487-4c66-86a7-df7dc17f57bc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming virtual investor conferences in March: Cowen 41 st Annual Health Care Conference Date: Tuesday, March 2, 2021Time: 11:50 a.m. ET H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9, 2021Time: 7:00 a.m. ET A live webcast of each presentation will be available on the Investors section of the company\u2019s website at https:\/\/www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;iTeos to Present at Upcoming Investor Conferences in March&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441599","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iTeos to Present at Upcoming Investor Conferences in March - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iTeos to Present at Upcoming Investor Conferences in March - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming virtual investor conferences in March: Cowen 41 st Annual Health Care Conference Date: Tuesday, March 2, 2021Time: 11:50 a.m. ET H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9, 2021Time: 7:00 a.m. ET A live webcast of each presentation will be available on the Investors section of the company\u2019s website at https:\/\/www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos &hellip; Continue reading &quot;iTeos to Present at Upcoming Investor Conferences in March&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T12:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iTeos to Present at Upcoming Investor Conferences in March\",\"datePublished\":\"2021-02-23T12:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/\"},\"wordCount\":388,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/\",\"name\":\"iTeos to Present at Upcoming Investor Conferences in March - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=\",\"datePublished\":\"2021-02-23T12:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-to-present-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iTeos to Present at Upcoming Investor Conferences in March\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iTeos to Present at Upcoming Investor Conferences in March - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/","og_locale":"en_US","og_type":"article","og_title":"iTeos to Present at Upcoming Investor Conferences in March - Market Newsdesk","og_description":"CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming virtual investor conferences in March: Cowen 41 st Annual Health Care Conference Date: Tuesday, March 2, 2021Time: 11:50 a.m. ET H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9, 2021Time: 7:00 a.m. ET A live webcast of each presentation will be available on the Investors section of the company\u2019s website at https:\/\/www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos &hellip; Continue reading \"iTeos to Present at Upcoming Investor Conferences in March\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T12:03:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iTeos to Present at Upcoming Investor Conferences in March","datePublished":"2021-02-23T12:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/"},"wordCount":388,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/","name":"iTeos to Present at Upcoming Investor Conferences in March - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=","datePublished":"2021-02-23T12:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzQwNSMzOTg4OTkxIzIyMDA1NjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-to-present-at-upcoming-investor-conferences-in-march\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iTeos to Present at Upcoming Investor Conferences in March"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441599"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441599\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}